Report - 2009
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td><strong>Grant Programmes 2009:</strong></td>
<td></td>
</tr>
<tr>
<td>EFSD</td>
<td>6</td>
</tr>
<tr>
<td>Clinical Research Grants in the Field of Diabetes</td>
<td></td>
</tr>
<tr>
<td>EFSD</td>
<td>7</td>
</tr>
<tr>
<td>New Horizons Collaborative Research Initiative</td>
<td></td>
</tr>
<tr>
<td>EFSD</td>
<td>8</td>
</tr>
<tr>
<td>EFSD Programme for the Development and Characterisation of Translational Preclinical Models for Type 2 Diabetes supported by <strong>Roche</strong></td>
<td></td>
</tr>
<tr>
<td>EFSD/Amylin</td>
<td>9</td>
</tr>
<tr>
<td>Paul Langerhans Grants on Interaction between Peripheral Tissues, the Gut and the Central Nervous System</td>
<td></td>
</tr>
<tr>
<td>EFSD/Chinese Diabetes Society/Lilly</td>
<td>10</td>
</tr>
<tr>
<td>Collaborative Diabetes Research Programme</td>
<td></td>
</tr>
<tr>
<td>EFSD/D-Cure</td>
<td>11</td>
</tr>
<tr>
<td>Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe</td>
<td></td>
</tr>
<tr>
<td>EFSD/GlaxoSmithKline</td>
<td>12</td>
</tr>
<tr>
<td>Programme in Immunomodulation and/or Modulation of the Incretin Pathway in Diabetes and its Complications</td>
<td></td>
</tr>
<tr>
<td>EFSD/JDRF/Novo Nordisk</td>
<td>13</td>
</tr>
<tr>
<td>European Programme in Type 1 Diabetes Research</td>
<td></td>
</tr>
<tr>
<td>EFSD/LifeScan</td>
<td>15</td>
</tr>
<tr>
<td>European Studies on Glucose Monitoring</td>
<td></td>
</tr>
<tr>
<td>EFSD/Lilly</td>
<td>16</td>
</tr>
<tr>
<td>European Diabetes Research Programme</td>
<td></td>
</tr>
<tr>
<td>EFSD/Lilly</td>
<td>17</td>
</tr>
<tr>
<td>Mental Health and Diabetes Programme</td>
<td></td>
</tr>
<tr>
<td>EFSD/Merck Sharp &amp; Dohme (MSD)</td>
<td>18</td>
</tr>
<tr>
<td>European Studies on Beta Cell Function and Survival: Basic Research Programme</td>
<td></td>
</tr>
<tr>
<td>EFSD/Merck Sharp &amp; Dohme (MSD)</td>
<td>19</td>
</tr>
<tr>
<td>European Studies on Islet Cell Function and Survival: Clinical Research Programme</td>
<td></td>
</tr>
</tbody>
</table>
EFSD/Novartis  
European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction  

EFSD/Novo Nordisk  
European Clinical Research Programme in Adolescents with Type 2 Diabetes  

EFSD/Pfizer  
European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes  

EFSD/sanofi-aventis  
European Research Programme in Micro- and Macrovascular Complications of Diabetes  

Fellowships 2009:  

EFSD Albert Renold  
Travel Fellowships supported by Merck Sharp & Dohme (MSD)  

EFSD/Chinese Diabetes Society/Lilly  
Research Fellowships  

EFSD/Lilly  
Research Fellowships  

New Programmes 2010:  

EFSD  
Research Programme in Diabetes and Cancer  

EFSD/Novo Nordisk  
Partnership for Diabetes Research in Europe  

Note: the above relates solely to programmes which have been officially agreed at the time of writing this Report.  

EFSD Review Committee Members  

EFSD Executive Committee and Administration
In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

**EFSD and its partners bring over Euro 62 Million to European diabetes research**

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over Euro 62 million to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the website of the Foundation: www.EuropeanDiabetesFoundation.org. An RFA (request for applications) for each Programme is printed in *Diabetologia* (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country as well as named non-European countries in the context of collaborative research programmes.
GRANT

PROGRAMMES

2009
Clinical Research Grants in the Field of Diabetes

Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity.

Funding Commitment and Instruments

Starting in 2007, this stand-alone EFSD Programme will commit a total of Euro 3.8 million towards clinical research in diabetes, with awards of up to Euro 300,000 over a period of up to three years, dependent upon the needs of the project.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Fredrik Karpe: University of Oxford - UK
Claes-Göran Östenson: Karolinska Institutet - Stockholm, Sweden
Johannes Romijn: Leiden University Medical Center - The Netherlands
Plan

There is a rich history of diabetes research throughout Europe and its associated states. Historically, however, funding for such research tends to be unevenly distributed.

The Foundation now seeks to redress in part this imbalance and to foster inter-regional collaboration in diabetes research throughout Europe by making available grants through the EFSD New Horizons Collaborative Research Initiative.

This Programme was created to foster inter-regional collaboration in diabetes research throughout Europe on a competitive basis. It is open to investigators working in institutions in the following countries and proposing to collaborate with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

Funding Commitment and Instruments

Up to Euro 1.2 million has been made available for the period 2009 - 2011 to fund basic and clinical research grants.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Ekaterine Berishvili: Tbilisi State Medical University - Georgia
Robert Hermann: Semmelweis University - Budapest, Hungary
Jana Vrbikova: Institute of Endocrinology - Prague, Czech Republic
Programme for the Development and Characterisation of Translational Preclinical Models for Type 2 Diabetes

Background

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life.

Plan

This Programme aims to encourage the development and characterisation of translational preclinical models for type 2 diabetes. One particular focus of the Programme will be the development of models of cardiomyopathies and chronic kidney disease.

Funding Commitment and Instruments

A total commitment of Euro 500,000 was made available for research grants totalling up to Euro 100,000 each.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Nicola Elvassore: Venetian Institute of Molecular Medicine - Padova, Italy
Patricia Iozzo: Institute of Clinical Physiology - Pisa, Italy
Michael Ristow: University of Jena - Germany
Eriika Savontaus: University of Turku - Finland
Paul Langerhans Grants on Interaction between Peripheral Tissues, the Gut and the Central Nervous System

Background

Amylin Pharmaceuticals Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialisation of innovative medicines. The company was founded in 1987 and since then has built a strong foundation on research and development.

Plan

EFSD and Amylin established a partnership in 2005 to provide grants for studies on the integrated physiology of the entero-insular axis and the brain in metabolic homeostasis. In 2009, the Programme offered grants up to Euro 100,000 for basic research and Euro 300,000 for clinical research, aimed at advancing current knowledge and stimulating European research in this domain.

In 2010, this Programme will be known as “EFSD/Amylin Paul Langerhans Grants on Interaction between the Brain, Gut, Liver and Periphery and its Importance in Diabetes”.

Funding Commitments and Instruments

Since its creation in 2005, and with additional funds up to and including 2009, the total funding commitment of the Partnership has reached Euro 1,656,000.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Gavin Bewick: Imperial College London - UK
Cendrine Cabou: Institute of Molecular Medicine - Toulouse, France
Patrick Gilon: University of Louvain - Brussels, Belgium
Fiona Gribble: University of Cambridge - UK
Programme for Collaborative Diabetes Research between China and Europe

Background

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

This partnership targets collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

Funding Commitment and Instruments

Total funding of **Euro 1.2 million** has been committed from 2008 – 2010. Two basic science research grants in the sum of up to Euro 100,000 and one clinical outcomes research grant in the sum of up to Euro 200,000 will be made available annually, for research to be carried out in China in collaboration with a European research institution.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- **Juliana Chan**: Chinese University of Hong Kong/Norman Sartorius - Geneva, Switzerland
- **Luo Feihong**: Fudan University/Carani Sanjeevi - Karolinska Institutet, Stockholm, Sweden
- **Zhiguang Zhou**: Central South University/David Leslie - University of London, UK
Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe

Background

D-Cure Diabetes Care in Israel R.A. (D-Cure) is a recently established non-profit organisation that aims to advance basic and clinical research into diabetes in Israel. This EFSD/D-Cure Programme is further supported by a charitable donation from another Israeli Foundation and the Berlin Charitable Trust.

Plan

This partnership programme encourages new projects aimed at advancing current knowledge in type 2 diabetes which are undertaken by young investigators working in Israel, in collaboration with an investigator working in another country in Europe.

Funding Commitment and Instruments

Starting in 2009, the partnership has committed a total of US$ 350,000 for research grants up to US$ 75,000 each.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Michael Elkin: Hadassah University – Jerusalem, Israel
Programme for the Study of Metabolic Toxicity in Diabetes

Background
Headquartered in the UK, and with operations based in the US, GlaxoSmithKline is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. Its mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

Plan
This EFSD and GlaxoSmithKline partnership is intended to stimulate and accelerate European research aimed at all aspects of metabolic cytotoxicity, with particular focus on molecular mechanisms of glucotoxicity and lipotoxicity, the mechanism of dysfunction and death of islet cells induced by hyperglycaemia and/or dyslipidaemia and the mechanism of insulin resistance induced by hyperglycaemia and/or dyslipidaemia. In 2010 this Programme will be known as “EFSD/GSK Programme in Immunomodulation and/or Modulation of the Incretin Pathway in Diabetes and its Complications”.

Funding Commitment and Instruments
Established in 2007 and since renewed annually, the total commitment of this partnership to date is Euro 1.5 million, made available as grants each of up to Euro 100,000.

Awards in 2009
Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Katarina Kos: Peninsula College - Exeter, UK
Valeriya Lyssenko: Lund University - Malmö, Sweden
Åke Sjöholm: Karolinska Institutet - Stockholm, Sweden
Bart Staels: University of Lille - France
Heike Weiss: Institute of Medical Biochemistry - Rostock, Germany
European Programme in Type 1 Diabetes Research

Background

The mission of the Juvenile Diabetes Research Foundation International (JDRF) is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research aims to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications. The specific goals of the Programme are: to promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to type 1 diabetes, to expedite the practical application of scientific advances in our understanding of the aetiology, pathogenesis, treatment and prevention of type 1 diabetes and its complications, to encourage clinical translational research bridging the bench and the bedside, and to increase awareness of type 1 diabetes research throughout Europe.

Funding Commitment and Instruments

The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research was established in 2001 and has since been renewed twice, with a combined commitment of Euro 11.75 million.
Grants of up to Euro 100,000 each were available, and in 2009 the Partnership considered on a case-by-case basis special requests for amounts of up to Euro 400,000 in total.

**Awards in 2009**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- Bertrand Duvillié: University of Paris 5 - France
- Costanza Emanueli: Bristol Royal Infirmary – UK
- Kathleen Gillespie: University of Bristol – UK
- Roberto Mallone: Hospital St. Vincent de Paul - Paris, France
- Ute Rogner: Pasteur Institute - Paris, France
- Lydia Sorokin: University of Münster - Germany
- Jaakko Tuomilehto: University of Helsinki - Finland
- Susan Wong: University of Bristol – UK
European Studies on Glucose Monitoring

Background

For more than two decades LifeScan has been committed to improving the quality of life for people with diabetes. LifeScan helped bring blood glucose testing out of the laboratory and into the hands of patients.

Plan

The EFSD/LifeScan Awards are intended to stimulate and accelerate European research aimed at improved understanding of the optimal use of glucose monitoring tools, both in type 1 and type 2 diabetes.

Funding Commitment and Instruments

The partnership was launched in 2005 and with additional funding in 2007 has committed a total of Euro 1.757 million, offered in the form of research grants. In 2008 and 2009, up to Euro 500,000 was available for each individual research project.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Sylvia Franc: Centre Hospitalier Sud Francilien - Corbeil Essones, France
David Owens: Cardiff University - UK
European Diabetes Research Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the EFSD/Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe. Launched in 2003 and renewed in 2006 and 2009, the Fund has now reached a total commitment of Euro 7.150 million to fund its various activities, including research grant and fellowship programmes.

Funding Commitment and Instruments

To date, the EFSD/Lilly Fund has contributed Euro 3.4 million towards the EFSD/Lilly Diabetes Research Programme, in the form of grants of up to Euro 100,000 each.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Hadi Al-Hasani: German Institute for Human Nutrition Potsdam-Rehbruecke - Nuthetal, Germany
Miriam Cnop: Free University of Brussels - Belgium
Yuval Dor: Hebrew University of Jerusalem - Israel
Sylvie Guerder: Physiopathology Centre of Toulouse-Purpan - France
Per-Anders Jansson: Sahlgrenska University Hospital - Gothenburg, Sweden
Daniel Konrad: University Children’s Hospital - Zurich, Switzerland
Anna Krook: Karolinska Institutet - Stockholm, Sweden
Charlotte Ling: Lund University - Malmö, Sweden
Margit Mahlapuu: Lundberg Laboratory - Gothenburg, Sweden
Michael Roden: Heinrich-Heine University - Düsseldorf, Germany
Yakup Tanriver: University Hospital Freiburg - Germany
Mental Health and Diabetes Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Eli Lilly and Company is in Indianapolis, Indiana, USA.

Plan

The EFSD/Lilly Mental Health and Diabetes Programme is intended to stimulate and accelerate European research aimed at clinical investigations into improved care of patients with diabetes and mental diseases including all forms of depression, schizophrenia and Alzheimer’s. Special emphasis should be given to improving the cooperation between psychiatric and diabetes care.

Funding Commitment and Instruments

A funding commitment of Euro 250,000 was made available to fund grants in 2009.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Marc de Hert: Catholic University Leuven - Kortenberg, Belgium collaborating with Christoph Correll: The Zucker Hillside Hospital - Berlin, Germany
Khalida Ismail: King's College London – UK collaborating with Frank Petrak: University of Bochum, Germany
European Studies on Beta Cell Function and Survival: Basic Research Programme

Background
Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan
These Programme awards are intended to stimulate and accelerate European research into all aspects of beta cell function and survival, with particular emphasis on the following: increasing beta cell mass/function, mechanisms of glucose-stimulated insulin secretion, mechanisms of beta cell dysfunction, including beta cell gluco- and lipotoxicity, non-invasive imaging of beta cells, and beta cell intermediary metabolism. The Programme will continue in 2010.

Funding Commitment and Instruments
This partnership Programme was established in 2005 and renewed in 2007 for a total commitment of Euro 3.2 million, to be distributed in the form of grants, each of up to Euro 100,000.

Awards in 2009
Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Sebastian Barg: Uppsala University - Sweden
Anne Grapin-Botton: Swiss Institute for Experimental Cancer Research - Lausanne, Switzerland
Jean-Christophe Jonas: Catholic University of Louvain - Brussels, Belgium
Hindrik Mulder: Lund University - Sweden
Romano Regazzi: University of Lausanne - Switzerland
Susanna Törnroth-Horsefield: University of Gothenburg - Sweden
European Studies on Islet Cell Function and Survival: Clinical Research Programme

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

These Programme awards are intended to stimulate and accelerate European research into clinical aspects of islet cell function and survival. Areas of particular interest include alterations in islet cell mass/function in diabetes and obesity, non-invasive imaging of islet cells, mechanisms of beta cell dysfunction in type 2 diabetes including beta cell gluco- and lipotoxicity, preservation or prevention of further loss of beta cell functional mass in individuals with impaired glucose tolerance, type 2 diabetes or early type 1 diabetes, methods for improving survival of transplanted islets or beta cells, and genetic defects that elucidate beta cell dysfunction in type 2 diabetes. In 2010 the title of this Programme will change to “EFSD/MSD European Clinical Research Programme on Incretins, Gut Physiology and Pancreatic Islets in Type 2 Diabetes”.

Funding Commitment and Instruments

This partnership Programme was established in 2008 for a total commitment of Euro 2.7 million to be distributed in the form of grants, each of up to Euro 300,000. In 2009 this amount was increased to Euro 400,000 each.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Marc Donath: University Hospital Zurich - Switzerland
David Matthews: Churchill Hospital – Oxford, UK
Thomas Pieber: University of Graz – Austria/Bernd Schultes: Interdisciplinary Obesity Center – St Gallen, Switzerland
EFSD
And
Novartis

European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction

Background

Novartis is a world leader in the research and development of products to protect and improve health and well-being. Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz.

Plan

The EFSD/Novartis European Programme for Clinical Research in the Field of Pancreatic Islet Dysfunction was created in order to stimulate and accelerate European clinical research into all aspects of pancreatic islet dysfunction. This Programme targets the clinical physiology and natural history of pancreatic islet dysfunction as it pertains to diabetes and other dysglycaemic conditions.

Funding Commitment and Instruments

A total of Euro 1.2 million was made available to fund research grants up to Euro 200,000 each from 2007 to 2009.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made the following awards:

Filip Knop: University of Copenhagen - Denmark
Cornelis Tack: Radboud University - Nijmegen, The Netherlands
European Clinical Research Programme in Adolescents with Type 2 Diabetes

**Background**

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 81 countries.

**Plan**

The goals of the Programme are to promote the highest quality of clinical medical research in Europe and its associated countries applicable to type 2 diabetes in adolescents, to expedite the practical application of scientific advances in our understanding of the psycho-social conditions, aetiology, pathogenesis, treatment and prevention of type 2 diabetes and its complications in adolescents, and to encourage clinical translational research bridging bench and bedside.

**Funding Commitments and Instruments**

This Programme replaced the EFSD/Novo Nordisk Programme in Type 2 Diabetes, with a combined total of **Euro 7.5 million**. Grants of up to Euro 300,000 were made available each year.

**Awards in 2009**

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Arie Nouwen: University of Birmingham – UK
European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes

**Background**

Pfizer is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. As part of its commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce cardiovascular risk, further our understanding of optimal treatment options, and ultimately improve the lives of people with diabetes.

**Plan**

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes. Research proposals should aim to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes and strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions. This Programme replaced the EFSD/Pfizer Resource Awards for European Diabetes Research.

**Funding Commitments and Instruments**

Since the establishment of this Partnership in 2004, a total of **Euro 1.8 million** has been made available. In the current programme, **Euro 1.2 million** has been allocated to fund research grants up to Euro 300,000 each.

**Awards in 2009**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- **Amalia Gastaldelli**: Institute of Clinical Physiology - Pisa, Italy
- **David Halon**: Lady Davis Carmel Medical Center - Haifa, Israel
European Research Programme in Micro- and Macrovascular Complications of Diabetes

Background

The sanofi-aventis Group is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

Plan

In 2009 the EFSD/sanofi-aventis Programme was established to focus on vascular complications of diabetes.

Funding Commitment and Instruments

A total of Euro 1.2 million has been committed to fund basic research projects up to Euro 100,000 and clinical research projects up to Euro 400,000. Since its creation in 2006, the EFSD/sanofi-aventis Partnership has made available Euro 3.625 million.

Awards in 2009

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

- Martin Andrassy: University of Heidelberg - Germany
- Cesare Patrone: Karolinska Institutet - Stockholm, Sweden
FELLOWSHIP

PROGRAMMES

2009
Albert Renold Fellowships, each of up to Euro 7,000, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months.

Albert Renold Fellowships are available throughout the year, and a decision is usually made within three weeks of applying.

In 2009 the following Fellowships were awarded:

Nina Petrova: travelled to Institute for Bioengineering of Catalonia - Barcelona, Spain
Cecilia Morgantini: travelled to University of California Los Angeles - USA
Ihor Shymanskyy: travelled to King’s College London – UK
Daniel Meier: travelled to University of Paris Descartes - France
Pál Maurovich Horvat: travelled to Harvard Medical School – Boston, USA
Claudia Lindtner: travelled to Mount Sinai School of Medicine – New York, USA
Esteban Gurzov: travelled to Mount Sinai Hospital -Toronto, Canada
Beatriz Sánchez-Solana: travelled to Gothenburg University - Sweden
Nicola Beer: travelled to National Institutes of Health – Washington, USA
Anna Rydén: travelled to University of Paris Descartes - France
Ermelindo Carreira Leal: travelled to Harvard Medical School - Boston, USA
Hermione Price: travelled to Free University – Amsterdam, The Netherlands
Nicole Ehrhardt: travelled to University of Bremen - Germany
Rosalba Portuesi: travelled to University of Ulm – Germany
Petra Augstein: travelled to University of Melbourne – Australia
Béla Horváth: travelled to National Institute of Health – Washington, USA
Rinke Stinestra: travelled to St Jude Children’s Hospital – Tennesssee, USA
Jeroen Lakerveld: travelled to Baker IDI Institute – Melbourne, Australia
Katja van den Hurk: travelled to Baker IDI Institute – Melbourne, Australia
Petros Thomakos: travelled to King’s College London – UK
Laura Steinbusch: travelled to Catholic University of Louvain – Brussels, Belgium
The objective of the EFSD/CDS/Lilly Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for fellowships may be accepted from applicants from China for study in a recognised research institution in Europe or its associated countries. Details of the partner organisations may be found under “EFSD/CDS/Lilly Collaborative Research Programme”.

Two Fellowships of up to Euro 25,000 each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

Total funding of Euro 300,000 has been committed from 2008 – 2010 for this Fellowship Programme.

In 2009 the following Fellowships were awarded:

Ning Li: University of Macau in collaboration with Pierre Maechler: University of Geneva - Switzerland
Feng Ning: Qingdao Centers for Disease Control in collaboration with Jaakko Kaprio: University of Helsinki - Finland
Luan Shu: Jiangsu Provincial Academy in collaboration with Kathrin Maedler: University of Bremen - Germany
The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education.

In 2009, the number of Fellowships available was increased from two to four, and this will also be the case in 2010. Each Fellowship Award is up to **Euro 50,000**. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships form part of the EFSD/Lilly European Diabetes Research Fund, further details of which may be found under “EFSD/Lilly Diabetes Research Programme”.

In 2009 the following Fellowships were awarded:

- Marie Björnholm: Karolinska Institutet - Stockholm, Sweden
- Ann Hammarstedt: The Lundberg Laboratory - Gothenburg, Sweden
- Paolo Rossetti: University of Perugia - Italy
- Giovanni Solinas: University of Fribourg - Switzerland
NEW PROGRAMMES

2010
Research Programme in Diabetes and Cancer

Plan
The EFSD Research Programme in Diabetes and Cancer has been established in order to stimulate and accelerate European research aimed at investigating why diabetes is associated with increased morbidity and mortality in certain forms of cancer. The role of diabetes therapy including molecular mechanisms is also of interest. Applications for projects carried out in collaboration between diabetes and cancer research institutions will be especially welcome.

Funding Commitment and Instruments

Euro 3 million will be made available over the next three years for research in the framework of the Programme. Research will be supported through the award of grants of up to Euro 100,000 for basic research projects and Euro 400,000 for clinical research projects.

Awards in 2010

The deadline for applications is 1 March 2010, with an anticipated award date of June 2010.
Partnership for Diabetes Research in Europe

Background

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 81 countries.

Plan

This new Programme will accept applications from all fields of diabetes research, including both basic and clinical research.

Funding Commitments and Instruments

This Programme continues the longstanding EFSD/Novo Nordisk Partnership, with a combined total commitment amounting to **Euro 10.5 million**. Grants of up to Euro 100,000 for basic research projects and Euro 400,000 for clinical research projects will be made available each year.

Awards in 2010

The deadline for applications is 1 April 2010, with an anticipated award date of July 2010.
Review Committee Members

EFSD is most grateful to the following colleagues who served on the various review committees of the 2009 partnership programmes:

Hadi Al-Hasani  
Angelo Avogaro  
Tadej Battelino  
Henning Beck-Nielsen  
Francesco Beguinot  
Jonathon Bodansky  
Riccardo Bonadonna  
Rémy Burcelin  
Corrado Cilio  
Miriam Cnop  
Stefano Del Prato  
Marc Donath  
Jürgen Eckel  
Decio Eizirk  
Paola Fioretto  
Peter Flatt  
Peter Grant  
Claus Gravholt  
Hans-Peter Hammes  
Torben Hansen  
Norbert Hermanns  
Rheinhard Holl  
Hannu Juvonen  
Fredrik Karpe  
Harald Klein  
Filip Knop  
Eckhard Lammert  
Agnés Lehuen  
Gil Leibowitz  
Sten Madsbad  
Rayez Malik  

Juris Meier  
Asimina Mitракou  
Noel Morgan  
Hindrik Mulder  
Andrea Natali  
Michael Nauck  
Philip Newsholme  
John Nolan  
Claes-Goran Östenson  
Ken Paterson  
Gianluca Perseghin  
John Petrie  
Jacques Philippe  
John Pickup  
Romano Regazzi  
Michael Roden  
Guy Rutter  
Shlomo Sasson  
James Shaw  
Olli Simell  
Michele Solimena  
Giatgen Spinas  
Norbert Stefan  
Ronald Stolk  
Mary C. Sugden  
Cees Tack  
Jeremy Tavaré  
Bernard Thorens  
Dietholm Tschöpe  
Peter van Endert
EXECUTIVE COMMITTEE and ADMINISTRATION

Executive Committee:

President: U Smith - Göteborg
Vice President: F Bosch - Barcelona
Vice President: A Boulton - Manchester
Honorary Secretary: M Stumvoll - Leipzig
Honorary Treasurer: G Spinas - Zürich
Editor in Chief - Diabetologia: E Gale - Bristol
Chairman PGESC: J Nolan - Dublin

Chairman - EFSD: P A Halban - Geneva

Scientific Board:
S Amiel - London
E Ferrannini - Pisa
J Ferrer - Barcelona
M Laakso - Kuopio
M Walker - London

Executive Director: V Jörgens – Düsseldorf

Administrators:
S Köhnen - Düsseldorf
K Sommer - Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)
Rheindorfer Weg 3
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0    Fax: + 49 211 75 84 69-29

Email: Foundation@easd.org

Bank details
Europäische Stiftung für Diabetesforschung – EFSD
Dresdner Bank
Königsallee 37
40212 Düsseldorf, Germany

Account / Konto: 600 2146 00    Code / BLZ: 300 800 00

SWIFT / BIC: DRES DE FF 300

IBAN: DE31 3008 0000 0600 2146 00
EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number: 15.2.1-St.767 and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547